Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Kammerer, S; Sokolowski, A; Hackl, H; Platzer, D; Jahn, SW; El-Heliebi, A; Schwarzenbacher, D; Stiegelbauer, V; Pichler, M; Rezania, S; Fiegl, H; Peintinger, F; Regitnig, P; Hoefler, G; Schreibmayer, W; Bauernhofer, T.
KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients.
Oncotarget. 2016; 7(51):84705-84717 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Bauernhofer Thomas
El-Heliebi Amin
Hoefler Gerald
Jahn Stephan
Kammerer Sarah
Peintinger Florentia
Pichler Martin
Platzer Dieter
Regitnig Peter
Rezania Simin
Schreibmayer Wolfgang
Schwarzenbacher Daniela
Sokolowski Armin
Stiegelbauer Verena
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 6
| | | | | |
Abstract:
Numerous studies showed abnormal expression of ion channels in different cancer types. Amongst these, the potassium channel gene KCNJ3 (encoding for GIRK1 proteins) has been reported to be upregulated in tumors of patients with breast cancer and to correlate with positive lymph node status. We aimed to study KCNJ3 levels in different breast cancer subtypes using gene expression data from the TCGA, to validate our findings using RNA in situ hybridization in a validation cohort (GEO ID GSE17705), and to study the prognostic value of KCNJ3using survival analysis. In a total of > 1000 breast cancer patients of two independent data sets we showed a) that KCNJ3 expression is upregulated in tumor tissue compared to corresponding normal tissue (p < 0.001), b) that KCNJ3 expression is associated with estrogen receptor (ER) positive tumors (p < 0.001), but that KCNJ3 expression is variable within this group, and c) that ER positive patients with high KCNJ3 levels have worse overall (p < 0.05) and disease free survival probabilities (p < 0.01), whereby KCNJ3 is an independent prognostic factor (p <0.05). In conclusion, our data suggest that patients with ER positive breast cancer might be stratified into high risk and low risk groups based on the KCNJ3 levels in the tumor.
Find related publications in this database (using NLM MeSH Indexing)
Age Factors -
Biomarkers, Tumor - metabolism
Breast Neoplasms - diagnosis
Breast Neoplasms - mortality
Cohort Studies -
Female -
G Protein-Coupled Inwardly-Rectifying Potassium Channels - metabolism
Gene Expression Regulation, Neoplastic -
Humans -
Lymphatic Metastasis -
Middle Aged -
Predictive Value of Tests -
Prognosis -
Receptor, ErbB-2 - metabolism
Survival Analysis -
Up-Regulation -

Find related publications in this database (Keywords)
KCNJ3
GIRK1
biomarker
estrogen receptor positive breast cancer
RNA in situ hybridization
© Meduni Graz Impressum